

ASX Announcement

Invion Limited (ASX Code IVX)

Grant of Waiver

8 October 2021

Invion Limited wishes to advise that it has been granted a waiver from ASX Listing Rule 10.13.5 to the extent necessary to permit the Company's Notice of Annual General Meeting ("**Notice**") to approve the issue of options to Mr Thian Chew, Mr Alan Yamashita, Mr Robert Merriel and Mr Alistair Bennallack (or their respective nominees) ("**Directors**") which when exercised will result in the issue of shares in lieu of their remuneration ("**Director Options**") not to state that Director Options will be issued no later than one month after the date of the Annual General Meeting, subject to the following conditions:

- 1.1 The Director Options are issued no later than 10 business days after the end of the relevant quarter.
- 1.2 The final Director Options are issued no later than 14 September 2022.
- 1.3 The Notice sets out that the Director Options upon exercise (in return for 100% of the director's fees for that period) will become fully paid ordinary shares in the capital of the Company ranking equally in all respects with the Company's existing shares on issue.
- 1.4 The Company's annual report for any period during which the Director Options are issued to the Director, discloses details of the number of Director Options that were issued to them, including the percentage of the Company's issued capital represented by those Director Options.
- 1.5 The terms of the waiver are immediately released to the market.

The Notice of Annual General Meeting will be despatched to shareholders in due course.

This announcement is authorised for release by the Company Secretary of Invion Limited.

Investor and Media enquiries:

Thian Chew (Chairman)
T: +61 3 8618 6843
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
T: +61 409 341 613
E: brendon@vantagepointpartners.com.au

About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited and its affiliates, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX). This announcement was approved for release by Thian Chew, Chairman of the Board. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

For personal use only